QuidelOrtho Corporation reported fourth quarter 2024 total revenue of $708 million, a decrease from $743 million in the prior year period, primarily due to lower COVID-19 and influenza revenue. Full-year 2024 total revenue was $2.78 billion, down from $3.00 billion in the prior year.
The company reported a GAAP diluted loss per share of $2.28 for Q4 2024 and a significant GAAP diluted loss per share of $30.16 for the full-year 2024, which included a non-cash goodwill impairment charge of approximately $1.82 billion. Adjusted diluted EPS for Q4 2024 was $0.63, compared to $1.17 in the prior year, and for the full-year 2024 was $1.85, down from $4.13.
Adjusted EBITDA for Q4 2024 was $150 million, with an adjusted EBITDA margin of 21%, while full-year 2024 adjusted EBITDA was $543 million, with a margin of 19.5%. For fiscal year 2025, QuidelOrtho issued guidance projecting total revenues between $2.60 billion and $2.81 billion, adjusted EBITDA between $575 million and $615 million, and adjusted diluted EPS between $2.07 and $2.57, with an adjusted EBITDA margin of 22%.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.